Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy

Shih-Chao Hsu; Sheng-Hsien Chen; Te-Hong Chen; Wei-Fan Hsu; Hung-Wei Wang; Chun-Chieh Yeh; Horng-Ren Yang; Hsueh-Chou Lai; Long-Bin Jeng

doi:10.12659/AOT.952135

24 March 2026 : Original article

Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy

Shih-Chao Hsu^{ABCDEF 1,2*}, Sheng-Hsien Chen^{AE 1,2}, Te-Hong Chen^{AE 1,2}, Wei-Fan Hsu^{AE 3}, Hung-Wei Wang^{AE 3,4}, Chun-Chieh Yeh^{AE 1,2,3,5}, Horng-Ren Yang^{AE 1,2}, Hsueh-Chou Lai^{AE 3}, Long-Bin Jeng^{AE 1,2}

DOI: 10.12659/AOT.952135

Ann Transplant 2026; 31:e952135

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 1 Comparison of progression-free survival (PFS) among 4 immune checkpoint inhibitor (ICI) treatment regimens used for recurrent hepatocellular carcinoma after liver transplantation.

Back to the Article

Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy

Your Privacy